TOSYMRA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tosymra, and what generic alternatives are available?
Tosymra is a drug marketed by Tonix Meds and is included in one NDA. There are eight patents protecting this drug.
This drug has ninety-one patent family members in twenty-nine countries.
The generic ingredient in TOSYMRA is sumatriptan. There are twenty-four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the sumatriptan profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tosymra
A generic version of TOSYMRA was approved as sumatriptan by LANNETT CO INC on February 19th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TOSYMRA?
- What are the global sales for TOSYMRA?
- What is Average Wholesale Price for TOSYMRA?
Summary for TOSYMRA
| International Patents: | 91 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 70 |
| Patent Applications: | 4,196 |
| Drug Prices: | Drug price information for TOSYMRA |
| What excipients (inactive ingredients) are in TOSYMRA? | TOSYMRA excipients list |
| DailyMed Link: | TOSYMRA at DailyMed |
Pharmacology for TOSYMRA
| Drug Class | Serotonin-1b and Serotonin-1d Receptor Agonist |
| Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
US Patents and Regulatory Information for TOSYMRA
TOSYMRA is protected by eight US patents.
Patents protecting TOSYMRA
Formulations comprising triptan compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE
Formulations comprising triptan compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE
Alkylglycoside compositions for drug administration
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions for drug administration
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE
Formulations comprising triptan compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE
Compositions for drug administration
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Formulations comprising triptan compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE
Formulations comprising triptan compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tonix Meds | TOSYMRA | sumatriptan | SPRAY;NASAL | 210884-001 | Jan 25, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Tonix Meds | TOSYMRA | sumatriptan | SPRAY;NASAL | 210884-001 | Jan 25, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Tonix Meds | TOSYMRA | sumatriptan | SPRAY;NASAL | 210884-001 | Jan 25, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for TOSYMRA
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Galpharm Healthcare Ltd. | Sumatriptan Galpharm | sumatriptan | EMEA/H/C/002140 |
Refused | yes | no | no | 2012-02-09 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for TOSYMRA
See the table below for patents covering TOSYMRA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 1789075 | SUBSTANCES AMELIORANT L'ABSORPTION DESTINEES A L'ADMINISTRATION DE MEDICAMENTS (ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION) | ⤷ Sign Up |
| China | 103189068 | Compositions for drug administration | ⤷ Sign Up |
| South Africa | 201202168 | FORMULATIONS COMPRISING TRIPTAN COMPOUNDS | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
